References
- Bossong MG, Van Dijk JP, Niesink RJ. Methylone and mCPP, two new drugs of abuse?. Addiction Biology 2005; 10: 321–323
- Brenneisen R, Geisshüsler S, Schorno X. Metabolism of cathinone to (–)-norephedrine and (–)-norpseudoephedrine. Journal of Pharmacy and Pharmacology 1986; 38: 298–300
- Caldwell J, Dring LG, Williams RT. Metabolism of [14C]methamphetamine in man, the guinea pig and the rat. Biochemical Journal 1972; 129: 11–22
- Cozzi NV, Sievert MK, Shulgin AT, Jacob III P, Ruoho AE. Metheathinone and 2-methylamino-1-(3,4-methylenedioxyphenyl) propan-1-one (methylone) selectively inhibit plasma membrane eatecholaminereuptake transporters. Society for Neuroscience Abstracts 1998; 24: 381.8
- Cozzi NV, Sievert MK, Shulgin AT, Jacob III P, Ruoho AE. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. European Journal of Pharmacology 1999; 381: 63–69
- Dal Cason TA, Young R, Glennon RA. Cathinone: An investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacology Biochemistry and Behavior 1997; 58: 1109–1116
- Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Pharmacological Reviews 2003; 55: 463–508
- Jacob III P, Shulgin AT. Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropioohenones as anti-depressant and anti-Parkinsonism agents. PCT International Applications19
- Kamata T, Katagi M, Kamata HT, Miki A, Shima N, Zaitsu K, Nishikawa M, Tanaka E, Honda K, Tsuchihashi H. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: Identification and quantification of its urinary metabolites. Drug Metabolism and Disposition 2006; 34: 281–287
- Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. Journal of Chromatography B 2003; 796: 421–427
- Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicology Letters 2000; 112–113: 133–142
- Shima N, Tsutsumi H, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H. Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users’ urine. Journal of Chromatography B 2006a; 830: 64–70
- Shima N, Tsutsumi H, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H. Urinary excretion of main metabolites of methamphetamine including p-hydroxymethamphetamine-sulfate and p-hydroxymethamphetamine-glucuronide in humans and rats. Xenobiotica 2006b; 36: 259–267
- Shima N, Tsutsumi H, Katagi M, Tsuchihashi H. Excretion of the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), the main urinary metabolite of MDMA, and their hydrolysis conditions. Japanese Journal of Forensic Toxicology 2005; 23: 124–125
- Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-a-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. Journal of Chromatography B 2003; 793: 377–388
- Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Current Drug Metabolism 2005; 6: 259–274
- Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, Kishi T, Tsuchihashi H. Isolation, identification and excretion profile of the principal irinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica 2005; 35: 107–116
- Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, Kishi T, Tsuchihashi H. metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. Journal of Analytical Toxicology 2006; 30: 38–43